AIM ImmunoTech is trading 10.87% down at $0.23 after an intraday reversal from initial buying sparked by its August 31, 2026, announcement of a broad U.S. patent covering Ampligen with pembrolizumab.
- The patent extends oncology protection through December 20, 2039, across multiple cancer indications.
- Broader risk-off sentiment may have added pressure, with major U.S. indices down roughly 0.5% and geopolitical concerns lifting oil prices.